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 Abstract 
  Aim:   To explore patterns of cerebral blood flow in patients with mild cognitive impairment 
(MCI), who (1) eventually deteriorate into overt dementia, with no particular focus on the type 
of dementia, or (2) do not appear to further deteriorate in their cognitive functions.   Methods:  
Thirty-seven MCI patients, with or without vascular pathology, were studied prospectively. The 
patients underwent   99m  Tc-HMPAO SPECT analysis at baseline. Possible clinical conversion into 
dementia within a 2-year period was assessed.   Results:   Nineteen patients had progressive MCI 
(PMCI), while 18 patients were considered clinically stable (SMCI). PMCI patients had more often 
abnormally low cerebral blood flow in at least one of the frontal, temporal, parietal or occipital 
lobes compared to SMCI patients (12/19 vs. 5/18; p = 0.049). At least one of the temporal regions 
was found to be abnormal in 9 PMCI patients in contrast to only 1 SMCI patient (p = 0.008). More 
specifically, blood flow in the medial portion of the left temporal region was abnormal in 8 PMCI 
patients, a pattern seen in 1 SMCI patient only (p = 0.019).   Conclusion:   The results suggest that 
blood flow reductions particularly in the left medial temporal region indicate an elevated risk 
of further cognitive decline in MCI patients.    Copyright © 2011 S. Karger AG, Basel 
  Published online: July 29, 2011 
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 Introduction 
  Mild cognitive impairment (MCI) represents a borderline condition between normal 
cognition and dementia. Subjects with MCI are at a higher risk of converting into overt de-
mentia than subjects with normal cognition   [1, 2]  . Since Alzheimer’s disease (AD) is consid-
ered to be the most common form of dementia   [3]  , prodromal AD is probably the most fre-
quent single MCI disorder. However, MCI is most likely a heterogeneous condition, i.e. an 
MCI patient who further deteriorates in his/her cognitions into overt dementia may develop 
one of many possible dementia disorders   [4]  . It would, therefore, seem relevant to study the 
eventual cognitive outcome in MCI patients with focus not only on AD, the presence or ab-
sence of which has been the endpoint in the vast majority of studies on MCI progression.
  It is probable that several dementia treatments with curative intention will be available in 
the fairly near future   [5, 6]  . In this context, there is reason to believe that the patient would 
benefit from treatment intervention already in the early phases of progressive cognitive dis-
orders. It is important, therefore, to acquire knowledge on markers for progressive degenera-
tive and vascular pathogenesis already in the incipient stages of dementia. Conversely, it is 
equally important to acquire knowledge on markers for non-progressive cognitive disorder.
  Magnetic resonance imaging studies have revealed an association between hippocampal 
atrophy and later development into overt dementia   [7]  , whereby left hippocampal atrophy 
may be a particularly sensitive predictor   [8]  . Furthermore, it has been demonstrated that the 
cerebrospinal fluid biomarker levels of     , phosphorylated      and amyloid     1–42   (A   42  ) are al-
tered already at the MCI stages in patients who will, eventually, suffer from AD   [9–11]  .
    Results from prospective FDG-PET studies suggest that subnormal metabolic rates of 
glucose consumption in temporoparietal and hippocampal regions in MCI patients  [12]  pre-
dict future conversion into overt AD. In a prospective study on cerebral blood flow imaging 
with SPECT, blood flow reductions in several brain regions, including the parietal and tem-
poral lobes and posterior cingulate, appeared to indicate future conversion from MCI into 
AD   [13] .
    The aim of the present prospective study was to further explore possible patterns of ce-
rebral blood flow reduction in a clinical population of MCI patients, who (1) eventually de-
teriorate into overt dementia, or (2) do not appear to further deteriorate in their cognitive 
functions. Patients with vascular pathology were not excluded, except for patients with a his-
tory of cerebral stroke. Separate quantification of left and right medial temporal lobe blood 
flow was included in the protocol. Blood flow was measured by way of hexamethyl propylene 
amine oxime (HMPAO)-SPECT, a technique which is relatively simple and widespread in 
medical care in comparison with the PET technique. Results from blood flow studies that 
utilize SPECT, instead of PET (which enables a higher-power resolution), may therefore be 
of more immediate importance in medical care.
  Materials  and  Methods 
 Study  Population 
  Thirty-seven patients with MCI were studied. They were part of the Gothenburg MCI 
Study, which is a longitudinal study on MCI and mild dementia performed at the Depart-
ment of Neuropsychiatry, Göteborg University, Sweden, and approved by the Ethics Com-
mittee of the University (reference: L 091-99). The patients had given their informed consent. 
Those included in the present study were the first consecutive subjects who (1) underwent 
SPECT analysis at baseline; (2) were assessed for MCI with a baseline score of 3 on the Glob-
al Deterioration Scale (GDS), and (3) did not have a history of major stroke.230
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  The categorization of patients with regard to MCI and (unspecified) dementia was based 
on anamnestic data and checklists for cognitive assessment: (1) Stepwise Comparative Status 
Analysis (STEP)  [14] , variables 13–20 (memory disturbance, disorientation, reduced abstract 
thinking, visuospatial disturbance, poverty of language, sensory aphasia, visual agnosia, and 
apraxia); (2) IFlex, which is a short form of the Executive Interview   [15]   (number-letter task, 
word fluency, anomalous sentence repetition, interference task, Luria’s hand sequences, and 
counting task); (3) Mini-Mental State Examination (MMSE)   [16]  , and (4) Clinical Dementia 
Rating (CDR)  [17] . The CDR assessment was based on information from both the subject and 
an informant. For inclusion, subjective and objective (by an informant) verifications of a 
progressive cognitive impairment for   1  6 months were required. In addition, a positive out-
come on STEP, IFlex, MMSE or CDR was required. Subjects with   1  2 positive outcomes on 
STEP or a score   !  25 on the MMSE were considered to fulfill criteria for dementia and were, 
consequently, not included in the present study   [18]  . The above algorithm is congruent with 
recent diagnostic recommendations   [2]  . Based on the scores, patients were classified accord-
ing to the GDS where 3 equals MCI and 4 mild dementia   [19]  .
    Nineteen patients converted clinically into dementia within 2 years (progressive MCI, 
PMCI), while 18 patients were considered clinically stable during the same time period (sta-
ble MCI, SMCI). Conversion into the dementia syndrome was assessed according to the al-
gorithm outlined above. The patients who converted to dementia suffered from the following 
clinical disorders: AD (n = 7) according to the NINCDS-ADRDA criteria   [20]  , subcortical 
vascular dementia, SVD, (n = 3) according to the criteria of Erkinjuntti et al.  [21] , mixed AD/
(subcortical) vascular dementia, MD (n = 7), progressive non-fluent aphasia (n = 1) accord-
ing to the  criteria of Neary et al.  [22] , and dementia non-ultra descriptum where no particu-
lar dementia disorder was possible to identify clinically (n = 1). Baseline demographics are 
presented in  table 1 . No statistical difference was found between the PMCI and SMCI groups 
with regard to age, gender, or baseline performance on MMSE.
    SPECT analysis was not included in any diagnostic procedure.
  SPECT  Imaging 
  All patients underwent   99m  Tc-HMPAO SPECT at baseline. About 1,000 MBq of   99m Tc-
HMPAO was administered intravenously after a 15- to 20-min period of resting in a quiet 
and dimly lit room. The subjects had their eyes closed during the resting period and the in-
jection. Imaging acquisitions were performed with a 3-headed Picker Irix    -camera  (Philips 
Medical Systems Inc., Hamburg, Germany) with high-resolution collimators about 45 min 
after the injection. A 128   !   128 pixel matrix was used and 90 projections were registered 
with an acquisition time of 45 s each. The image reconstruction was performed with filtered 
back-projection and a Butterworth filter (cutoff 0.5 cycles/cm) on a Picker Odyssey FX820 
PMCI SMCI
Age, years Mean
SD
Range
66.9
6.7
51–78
66.5
7.4
54–77
Gender Males
Females
8
11
11
7
MMSE Mean
SD
Range
27.3
1.5
23–29
28.1
1.7
24–30
Table 1. D  emographic data and 
MMSE scores at baseline231
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System (Philips Medical Systems Inc). Attenuation was modeled to be uniform (linear at-
tenuation coefficient = 0.11 cm  –1  ) inside the skull volume. No scatter subtraction was per-
formed. The resulting transaxial slice images were then transferred to a software for semi-
quantitative analysis (EXINI brain  TM  ; EXINI diagnostics AB, Lund, Sweden). The software 
comprises a 3-dimensional method based on a brain-shaped model and the active shape al-
gorithm. The method defines the surface shape of the brain and then projects the maximum 
counts 0–1.5 cm deep for designated surface points. These surface projection values are di-
vided into cortical regions representing the different lobes and presented relative to the whole 
cortex, cerebellum, or cerebellar maximum. The whole brain and the cerebellum are the 
most common reference regions used, but they do not always represent the best choice. In 
patients with reduced blood flow in these regions, quantitative data may be inaccurate. As 
an alternative reference region, the maximum value of the cerebellum was added to the quan-
tification method.
    The mean time between baseline clinical assessment and SPECT imaging was 140 (SD 
77) days in the PMCI group and 105 (SD 81) days in the SMCI group; the difference is statis-
tically not significant (p = 0.187).
  Image  Analysis 
  The brain surface is automatically outlined 3-dimensionally by the program. The corti-
cal blood flow is calculated in relation to the blood flow of one of three reference regions 
(cortex – the whole cortical part of the brain; cerebellum  tot   – the cortical part of cerebellum, 
and cerebellum  max   – the maximum intensity of cerebellum). The relative blood flow values 
are compared to the corresponding values of a normal database and z-values are calculated. 
The normal group consisted of 30 healthy volunteers, 20 females and 10 males, with a mean 
age of 74.4 years (SD 7.8; range 64–98). Mean z-values are calculated of each of 10 brain re-
gions (frontal lobe dx/sin/med, temporal lobe dx/sin/med-dx/med-sin), parietal lobe (dx/sin) 
and the whole occipital lobe. The differences in blood flow between the left and right sides 
are also calculated for the frontal, temporal and parietal lobes, and compared to the corre-
sponding normal values.
  Statistical  Analyses 
  Relationships between categorical variables were tested using Fisher’s exact test and re-
lationships between continuous variables were tested using Student’s t test.
  R e s u l t s  
  The number of patients with abnormal baseline findings in the parietal, temporal, fron-
tal, and occipital lobes are presented in   table 2  . Patients with PMCI had more frequently ab-
normal findings in the cerebral blood flow in at least 1 of the 4 regions compared to the SMCI 
group (12/19 vs. 5/18; p = 0.049), using the cerebellum  max   normalization method. The 12 
cases included 4 of the 7 AD patients and 7 of the 10 dementia patients with obvious cere-
brovascular disease (SVD + MD; non-significant difference between the patient groups). The 
17 patients with reduced blood flow had a mean MMSE of 27.8 compared to a mean MMSE 
of 27.6 in the remaining patients without reduced blood flow. This difference was not sig-
nificant, i.e. a relationship between cognitive performance and reduced blood flow could not 
be found. At least one of the temporal regions was abnormal in 9 of the PMCI patients, but 
only in 1 SMCI patient using the same normalization method (p = 0.008). The 9 cases in-
cluded 2 of the 7 AD patients and 6 of the 10 SVD + MD patients (non-significant difference 
between the patient groups). More specifically, the blood flow in the medial portion of the 232
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left temporal region was abnormally low in 8 PMCI patients, a pattern seen only in 1 SMCI 
patient (p = 0.019). There were no significant differences in blood flow between the patient 
groups in the frontal, parietal, and occipital lobes.
    Measurements of relative blood flow as a continuous variable are presented in   table 3  . 
No differences in mean z-values (standard deviations from the mean of a normal database) 
between PMCI and SMCI were found in the parietal, temporal, frontal, or occipital lobes. 
    In addition, a significant side difference in cerebral blood flow was found in 11 patients, 
7 PMCI (3 MD, 2 AD, 1 SVD, and 1 progressive non-fluent aphasia) and 4 SMCI (  table 4  ). In 
all cases, the cerebral blood flow was lower on the left compared to the right side.
  Discussion 
 The present study demonstrated that MCI patients who deteriorated into overt dementia 
within the following 2-year period exhibited more often abnormal cerebral blood flow at 
baseline than did patients with SMCI. The most distinct finding was a blood flow reduction 
in the medial portion of the left temporal region in 8 of 19 PMCI patients, a pattern seen in 
1 of 18 SMCI patients only (using the cerebellum  max   method).
    We did not find any significant differences in the measurements of relative blood flow 
as a continuous variable between the PMCI and SMCI groups. The analysis was made sepa-
rately for the frontal, temporal, parietal and occipital lobes. Abnormal findings in at least one 
of these regions were, however, more frequent in the PMCI group compared to the SMCI 
group. This finding indicates that the PMCI patients are a heterogeneous group and that ab-
normalities in their cerebral blood flow can appear in different locations rather than as a 
homogeneous gradual decrease in blood flow in a specific location.
    It is fairly well established that blood flow reductions in parietal brain regions, medial 
temporal regions, precuneus and posterior cingulate gyrus predict cognitive decline   [13, 
23–25]   and the development of clinically manifest AD in MCI patients   [26]  . Also, the pres-
Table 2. N umber of patients with significantly decreased blood flow in 10 brain regions [frontal lobe (right, 
left, medial), temporal lobe (right, left, right medial, left medial), parietal lobe (right, left) and occipital 
lobe]
Normalization Cortex Cerebellumtot Cerebellummax
PMCI
(n = 19)
SMCI
(n = 18)
PMCI
(n = 19)
SMCI
(n = 18)
PMCI
(n = 19)
SMCI
(n = 18)
Frontal dx 0 0 1 1 1 0
Frontal sin 3 2 4 2 2 2
Frontal med 0 0 1 0 1 2
Temporal dx 0 0 1 1 1 1
Temporal sin 1 1 2 2 1 1
Temporal med dx 3 2 5 3 5 1
Temporal med sin 5 3 8 2 8* 1*
Parietal dx 7 5 7 2 6 4
Parietal sin 8 9 9 4 6 4
Occipital 1 0 1 2 0 2
Total 16 13 12 8 12** 5**
Cor tex,  cerebellumtot, cerebellummax: reference regions for blood flow calculation (see Image Analysis 
above). * p = 0.019, ** p = 0.049.233
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ence of AD-typical cortical atrophy on MRI appears to predict future cognitive deterioration 
in patients with MCI   [27]  . With regard to the possible importance of asymmetrical blood 
flow patterns, presence of left-sided reduction in the posterior cingulate gyrus has been re-
ported in a SPECT study on PMCI   [28]  . Also, a SPECT study by Nobili et al.   [29]   demon-
strated reduced blood flow in the left hippocampus     in amnestic MCI. Conversely, another 
SPECT study demonstrated right-sided parietal and hippocampal blood flow reductions in 
PMCI   [30]  . One study employing functional MRI demonstrated   increased   blood flow in the 
left hippocampus in MCI, a finding which was interpreted as a possible (transient) compen-
satory mechanism in incipient AD   [31]  . In summary, the present study and the literature 
provide results which appear to be contradictory with regard to the existence and possible 
importance of asymmetrical cerebral blood flow in MCI.
    There was no significant difference in frontal lobe blood flow between PMCI and SMCI 
patients in the present study. This finding is in contrast to findings in SPECT studies by 
Huang et al.   [23, 24]  , in which blood flow in frontal brain regions of PMCI patients was in-
creased compared with SMCI patients and healthy controls. In a recent MR/SPECT study on 
amnestic MCI   [32]  , a   negative   correlation was found between entorhinal/hippocampal vol-
umes and blood flow in frontal brain regions – and a  positive  correlation between entorhinal/
Table 3. B  lood flow in relation to a normal database presented in z-values (standard deviations from mean)
Normalization Cortex Cerebellumtot Cerebellummax
PMCI
(n = 19)
SMCI
(n = 18)
PMCI
(n = 19)
SMCI
(n = 18)
PMCI 
(n = 19)
SMCI
(n = 18)
Frontal dx 0.68+1.48 0.32+0.88 –0.24+1.29 –0.27+0.89 –0.35+0.95 –0.27+0.92
Frontal sin –0.78+1.17 –0.76+0.70 –0.93+1.10 –0.78+0.81 –0.92+0.86 –0.70+0.87
Frontal med –0.33+0.76 –0.34+0.93 –0.63+0.89 –0.54+0.87 –0.71+0.82 –0.55+1.06
Temporal dx 1.21+1.26 1.31+0.85 0.16+1.39 0.39+1.21 –0.02+1.04 0.26+1.13
Temporal sin 0.03+1.52 0.12+0.91 –0.58+1.35 –0.36+1.12 –0.59+1.13 –0.33+1.04
Temporal med dx –0.99+0.85 –0.79+1.03 –1.20+1.01 –0.94+0.85 –1.18+1.01 –0.88+0.83
Temporal med sin –1.55+1.80 –1.31+0.73 –1.60+1.51 –1.32+0.60 –1.52+1.49 –1.21+0.74
Parietal dx –1.77+0.95 –1.44+0.97 –1.68+0.92 –1.35+0.86 –1.51+0.68 –1.17+0.83
Parietal sin –1.97+1.08 –1.60+1.03 –1.82+1.03 –1.46+0.84 –1.63+0.84 –1.27+0.86
Occipital –0.43+1.17 –0.70+0.63 –0.86+0.72 –0.89+0.83 –0.80+0.61 –0.75+0.87
No   differences in mean values between PMCI and SMCI were statistically significant (t test).
Table 4.   Number of patients with significant side differences in cerebral blood flow with regard to frontal, 
temporal, and parietal lobes, respectively
Lobes PMCI (n = 19) S  MCI (n = 18) p value
L < R R < L L   < R R < L PMCI vs. SMCI L < R vs. R < L
Frontal 7 0 4 0 NS 0.003
Temporal 4 0 0 0 NS NS
Parietal 1 0 0 0 NS NS
Total 7 0 4 0 NS 0.003
Tot  al: number of patients with significant side difference in at least 1 region. L < R and R < L = Sig-
nificantly lower cerebral blood flow in the left region than in the right region and vice versa.234
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hippocampal volumes and blood flow in the posterior cingulate gyrus, whereby the latter 
finding possibly reflects deafferentation. Taken together, the above results in the literature 
indicate the presence of transient compensatory frontal functions in subgroups of MCI pa-
tients prior to conversion into overt dementia.
    In conclusion, the results of the present study support the view that blood flow reduc-
tions in the left medial temporal region indicate an elevated risk of further cognitive decline 
in MCI patients. Unfortunately, the SPECT literature in the field of MCI prognostics reports 
the use of varying progression markers and varying brain regions of interest. Furthermore, 
inclusion criteria may vary. In the present study, for instance, information on left/right hand-
edness was not included in the protocol. These circumstances make comparisons between 
studies somewhat difficult   [33]  .
    Finally, a note on the choice of the imaging method is worth being mentioned. FDG-
PET, one alternative imaging technique, appears to be a more distinct marker of cognitive 
decline compared to SPECT   [33]  . The FDG-PET technique appears to have the ability even 
to predict future MCI in clinically healthy persons   [34]  . Furthermore, Pittsburgh Com-
pound-B PET appears to be a promising method for early identification of emerging AD  [35, 
36] . However, the SPECT technique is in most countries more often available than PET. Data 
from prediction studies based on SPECT and robust assessments of cognitive status, such as 
GDS, would, therefore, possibly be of more immediate importance in general health care.
  Acknowledgments 
 The authors thank Ms. Eva Bringman, Ms. Christina Holmberg and Ms. Ewa Styrud for 
excellent assistance in the study, and Mr. Mattias Göthlin for expert database handling. This 
study was supported by grants from the Alzheimerfonden, Demensförbundet, Sahlgrenska 
University Hospital, Stiftelsen Psykiatriska forskningsfonden, Swedish Brain Power and the 
Swedish Research Council.
  Disclosure  Statement 
 Lars Edenbrandt is employed and shareholder in EXINI diagnostics AB, which owns the 
software EXINI brain described in this paper.
 
 References 
    1  Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;    256:   183–194. 
    2  Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Al-
bert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini 
E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive 
impairment – beyond controversies, towards a consensus: report of the international working group 
on mild cognitive impairment. J Intern Med 2004;    256:   240–246. 
    3  Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, 
Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M, Alzheimer’s Disease Interna-
tional: Global prevalence of dementia: a Delphi consensus study. Lancet 2005;    366:   2112–2117. 
    4  Maioli F, Coveri M, Pagni P, Chiandetti C, Marchetti C, Ciarrocchi R, Ruggero C, Nativio V, Onesti 
A, D’Anastasio C, Pedone V: Conversion of mild cognitive impairment to dementia in elderly sub-
jects: a preliminary study in a memory and cognitive disorder unit. Arch Gerontol Geriatr 2007;   
 44(suppl  1):233–241. 235
Dement Geriatr Cogn Disord Extra 2011;1:228–236
 DOI:  10.1159/000329447 
EXTRA
  Edman et al.: Asymmetric Cerebral Blood Flow in MCI 
www.karger.com/dee
  © 2011 S. Karger AG, Basel 
  Published online: July 29, 2011 
    5  Bergmans BA, De Strooper: Gamma-secretases: from cell biology to therapeutic strategies. Lancet 
Neurol 2010;    9:   215–226. 
    6  Lemere CA, Masliah E: Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat 
Rev Neurol 2010;    6:   108–119. 
    7  Pihlajamäki M, Jauhiainen AM, Soininen H: Structural and functional MRI in mild cognitive im-
pairment. Curr Alzheimer Res 2009;    6:   179–185. 
    8  Eckerström C, Olsson E, Borga M, Ekholm S, Ribbelin S, Rolstad S, Starck G, Edman A, Wallin A, 
Malmgren H: Small baseline volume of left hippocampus is associated with subsequent conversion 
of MCI into dementia: the Göteborg MCI study. J Neurol Sci 2008;    272:   48–59. 
    9  Herukka SK, Hallikainen M, Soininen H, Pirttilä T: CSF A    42 and tau or phosphorylated tau and 
prediction of progressive mild cognitive impairment. Neurology 2005;    64:   1294–1297. 
  10  Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF 
biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-
up study. Lancet Neurol 2006;    5:   228–234. 
  11  Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wal-
lin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K: 
Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with 
subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospec-
tive cohort study. Lancet Neurol 2009;    8:   619–627. 
  12  de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint 
Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H: Imaging and CSF studies in the 
preclinical diagnosis of Alzheimer’s disease. Ann NY Acad Sci 2007;    1097:   114–145. 
  13  Borroni B, Anchisi D, Paghera B, Vicini B, Kerrouche N, Garibotto V, Terzi A, Vignolo LA, Di Luca 
M, Giubbini R, Oadovani A, Perani D: Combined   99m Tc-ECD SPECT and neuropsychological studies 
in MCI for the assessment of conversion to AD. Neurobiol Aging 2006;    27:   24–31. 
  14  Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M: Stepwise compar-
ative status analysis (step): a tool for identification of regional brain syndromes in dementia. J Geriatr 
Psychiatry Neurol 1996;    9:   185–199. 
  15  Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the ex-
ecutive interview. J Am Geriatr Soc 1992;    40:   1221–1226. 
  16  Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cog-
nitive state of patients for the clinician. J Psychiatric Res 1975;    12:   189–198. 
  17  Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for demen-
tia of the Alzheimer type. Int Psychogeriatr 1997;     9(suppl 1):173–176, discussion 177–178. 
 18  Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A: The Göteborg MCI study: mild 
cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005;    76:   1485–
1490. 
 19  Reisberg B, Ferris SH, de Leon MJ, Crook T: Global deterioration scale (GDS). Psychopharmacol Bull 
1988;    24:   661–663. 
  20  McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alz-
heimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of 
Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;    34:   939–944. 
  21  Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Des-
mond DW: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm 
Suppl 2000;    59:   23–30. 
  22  Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, 
Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a con-
sensus on clinical diagnostic criteria. Neurology 1998;    51:   1546–1554. 
  23  Huang C, Wahlund LO, Almkvist O, Elehu D, Svensson L, Jonsson T, Winblad B, Julin P: Voxel- and 
VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild 
cognitive impairment. Neuroimage 2003;    19:   1137–1144. 
 24  Huang C, Eidelberg D, Habeck C, Moeller J, Svensson L, Tarabula T, Julin P: Imaging markers of mild 
cognitive impairment: multivariate analysis of CBF SPECT. Neurobiol Aging 2007;    28:   1062–1069. 
  25  Matsuda H: The role of neuroimaging in mild cognitive impairment. Neuropathology 2007;    27:   570–
577. 236
Dement Geriatr Cogn Disord Extra 2011;1:228–236
 DOI:  10.1159/000329447 
EXTRA
  Edman et al.: Asymmetric Cerebral Blood Flow in MCI 
www.karger.com/dee
    © 2011 S. Karger AG, Basel
  Published online: July 29, 2011 
  26  Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S: Combined rCBF and 
CSF biomarkers predict progression from mild cognitive impairment to Alzheimer’s disease. Neu-
robiol Aging 2009;    30:   165–173. 
  27  McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ Jr, Holland D, Karow DS, Pung CJ, Brew-
er JB, Dale AM, Alzheimer’s Disease Neuroimaging Initiative: Alzheimer disease: quantitative struc-
tural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive 
impairment. Radiology 2009;    251:   195–205. 
  28  Huang C, Wahlund LO, Svensson L, Winblad B, Julin P: Cingulate cortex hypoperfusion predicts 
Alzheimer’s disease in mild cognitive impairment. BMC Neurol 2002;    2:   9. 
  29  Nobili F, Frisoni GB, Portet F, Verhey F, Rodriguez G, Caroli A, Touchon J, Calvini P, Morbelli S, De 
Carli F, Guerra UP, Van de Pol LA, Visser PJ: Brain SPECT in subtypes of mild cognitive impairment. 
Findings from the DESCRIPA multicenter study. J Neurol 2008;    255:   1344–1353. 
  30  Habert MO, Horn JF, Sarazin M, Lotterie JA, Puel M, Onen F, Zanca M, Portet F, Touchon J, Verny 
M, Mahieeux F, Giron A, Fertil B, Dubois B: Brain perfusion SPECT with an automated quantitative 
tool can identify prodromal Alzheimer’s disease among patients with mild cognitive impairment. 
Neurobiol Aging 2011;    32:   15–23. 
  31  Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM: Mild cognitive impairment and 
Alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 2009;    250:   856–
866. 
  32  Guedj E, Barbeau EJ, Didic M, Felician O, de Laforte C, Ranjeva JP, Poncet M, Cozzone PJ, Mundler 
O, Ceccaldi M: Effects of medial temporal lobe degeneration on brain perfusion in amnestic MCI of 
AD type: deafferentation and functional compensation? Eur J Nucl Med Mol Imaging 2009;    36:   1101–
1112. 
  33  Yuan Y, Gu ZX, Wei WS: Fluorodeoxyglucose-positron-emission tomography, single-photon emis-
sion tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease 
in patients with mild cognitive impairment: a meta-analysis. Am J Neuroradiol 2009;    30:   404–410. 
 34  Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ: Hippocam-
pal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2008;    29:   676–
692. 
  35  Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, 
Nordberg A: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neu-
robiol Aging 2008;    29:   1456–1465. 
  36  Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, Ferrucci L, Mathis CA, Klunk WE, Wong 
DF, Resnick SM: Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?
J Nucl Med 2008;    49:   1465–1471. 
  